HRP20220497T1 - Spoj morfolinilpiridona - Google Patents
Spoj morfolinilpiridona Download PDFInfo
- Publication number
- HRP20220497T1 HRP20220497T1 HRP20220497TT HRP20220497T HRP20220497T1 HR P20220497 T1 HRP20220497 T1 HR P20220497T1 HR P20220497T T HRP20220497T T HR P20220497TT HR P20220497 T HRP20220497 T HR P20220497T HR P20220497 T1 HRP20220497 T1 HR P20220497T1
- Authority
- HR
- Croatia
- Prior art keywords
- trifluoromethyl
- methylmorpholin
- pyridin
- pharmaceutically acceptable
- image
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187567 | 2017-08-23 | ||
| PCT/EP2018/072791 WO2019038390A1 (en) | 2017-08-23 | 2018-08-23 | MORPHOLINYLPYRIDONE COMPOUNDS |
| EP18759105.2A EP3672962B1 (en) | 2017-08-23 | 2018-08-23 | Morpholinylpyridone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220497T1 true HRP20220497T1 (hr) | 2022-05-27 |
Family
ID=59686888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220497TT HRP20220497T1 (hr) | 2017-08-23 | 2018-08-23 | Spoj morfolinilpiridona |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11560374B2 (enExample) |
| EP (2) | EP4056569A1 (enExample) |
| JP (2) | JP7199736B2 (enExample) |
| KR (1) | KR102732013B1 (enExample) |
| CN (3) | CN116444510A (enExample) |
| AU (2) | AU2018320419B2 (enExample) |
| CY (1) | CY1125117T1 (enExample) |
| DK (1) | DK3672962T3 (enExample) |
| ES (1) | ES2910157T3 (enExample) |
| HR (1) | HRP20220497T1 (enExample) |
| HU (1) | HUE058661T2 (enExample) |
| IL (3) | IL302077A (enExample) |
| LT (1) | LT3672962T (enExample) |
| PL (1) | PL3672962T3 (enExample) |
| PT (1) | PT3672962T (enExample) |
| RS (1) | RS63109B1 (enExample) |
| SI (1) | SI3672962T1 (enExample) |
| SM (1) | SMT202200169T1 (enExample) |
| TW (2) | TWI803511B (enExample) |
| WO (1) | WO2019038390A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022115543A1 (en) * | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of vps34 inhibitors |
| CA3199995A1 (en) * | 2020-11-25 | 2022-06-02 | Daniel L. Flynn | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
| US12414955B2 (en) | 2020-11-25 | 2025-09-16 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of VPS34 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006034473A2 (en) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| WO2011058478A1 (en) * | 2009-11-16 | 2011-05-19 | Pfizer Inc. | Substituted triazolopyrimidines as pde8 inhibitors |
| JP2014500308A (ja) | 2010-12-21 | 2014-01-09 | ノバルティス アーゲー | Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物 |
| EP2655375B1 (fr) | 2010-12-23 | 2014-12-03 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| FR2992314B1 (fr) * | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| EP3042900B1 (en) * | 2013-08-29 | 2020-09-23 | Fujifilm Corporation | Novel morpholine derivative or salt thereof |
| MX2016009135A (es) | 2014-01-14 | 2016-10-05 | Millennium Pharm Inc | Heteroarilos y usos de estos. |
| US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| HRP20201400T1 (hr) * | 2016-02-19 | 2020-11-27 | Sprint Bioscience Ab | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa |
| CN108884067B (zh) | 2016-02-19 | 2021-01-08 | 思普瑞特生物科学公司 | 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物 |
-
2018
- 2018-08-23 LT LTEPPCT/EP2018/072791T patent/LT3672962T/lt unknown
- 2018-08-23 SM SM20220169T patent/SMT202200169T1/it unknown
- 2018-08-23 US US16/639,902 patent/US11560374B2/en active Active
- 2018-08-23 DK DK18759105.2T patent/DK3672962T3/da active
- 2018-08-23 AU AU2018320419A patent/AU2018320419B2/en active Active
- 2018-08-23 CN CN202310448700.6A patent/CN116444510A/zh active Pending
- 2018-08-23 WO PCT/EP2018/072791 patent/WO2019038390A1/en not_active Ceased
- 2018-08-23 TW TW107129499A patent/TWI803511B/zh not_active IP Right Cessation
- 2018-08-23 EP EP22153292.2A patent/EP4056569A1/en not_active Withdrawn
- 2018-08-23 IL IL302077A patent/IL302077A/en unknown
- 2018-08-23 RS RS20220357A patent/RS63109B1/sr unknown
- 2018-08-23 PT PT187591052T patent/PT3672962T/pt unknown
- 2018-08-23 HR HRP20220497TT patent/HRP20220497T1/hr unknown
- 2018-08-23 JP JP2020510087A patent/JP7199736B2/ja active Active
- 2018-08-23 PL PL18759105T patent/PL3672962T3/pl unknown
- 2018-08-23 CN CN201880060742.XA patent/CN111108102B/zh active Active
- 2018-08-23 ES ES18759105T patent/ES2910157T3/es active Active
- 2018-08-23 TW TW112116474A patent/TW202348601A/zh unknown
- 2018-08-23 HU HUE18759105A patent/HUE058661T2/hu unknown
- 2018-08-23 SI SI201830624T patent/SI3672962T1/sl unknown
- 2018-08-23 CN CN202310448740.0A patent/CN116462674A/zh active Pending
- 2018-08-23 EP EP18759105.2A patent/EP3672962B1/en active Active
- 2018-08-23 KR KR1020207007564A patent/KR102732013B1/ko active Active
-
2020
- 2020-02-20 IL IL272815A patent/IL272815B/en unknown
-
2022
- 2022-04-14 CY CY20221100283T patent/CY1125117T1/el unknown
- 2022-04-25 IL IL292489A patent/IL292489B2/en unknown
- 2022-12-13 JP JP2022198452A patent/JP2023021268A/ja not_active Ceased
- 2022-12-19 US US18/084,208 patent/US20230234949A1/en not_active Abandoned
-
2023
- 2023-12-22 AU AU2023285995A patent/AU2023285995A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| HRP20221454T1 (hr) | Piridinamin-piridonski i pirimidinamin-piridonski spojevi | |
| IL274816B2 (en) | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | |
| IL273000B2 (en) | Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1) | |
| JP2009516685A5 (enExample) | ||
| HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| JP2010513444A5 (enExample) | ||
| AR074426A1 (es) | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2015531366A5 (enExample) | ||
| RU2008145225A (ru) | Соединения индазола и способы ингибирования cd7 | |
| CA2982267C (en) | Novel dgat2 inhibitors | |
| HRP20220497T1 (hr) | Spoj morfolinilpiridona | |
| JP2016513660A5 (enExample) | ||
| HRP20192224T1 (hr) | Inhibitori proteinske kinaze c i metode za njihovu primjenu | |
| JP2019505595A5 (enExample) | ||
| SI1702917T1 (en) | The amide derivatives and the drug | |
| RU2017145929A (ru) | МОДУЛЯТОРЫ ROR ГАММА(RORγ) | |
| JP2018505876A5 (enExample) | ||
| HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
| HRP20210320T1 (hr) | Spojevi heteroarila za liječenje oftalmičkih bolesti | |
| JP2005516037A5 (enExample) | ||
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| JP2019530708A5 (enExample) |